Quanterix Releases Financial Results for the Fourth Quarter of 2024
Delivers seventh consecutive quarter of double-digit revenue growth
BILLERICA, Mass.--(BUSINESS WIRE)--March 17, 2025--
Quanterix Corporation $(QTRX)$, a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024.
"During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and oncology, which will materially grow our addressable market, increase leverage and scale. Our announced acquisition of Akoya Biosciences is an important step forward in the execution of this strategy."
On January 10, 2025, Quanterix announced a definitive merger agreement to acquire Akoya in an all-stock transaction. The proposed combination will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, uniquely positioning the company to accelerate market development of new clinical tests. The transaction is expected to close in the second quarter of 2025, subject to certain closing conditions including approval by both companies' shareholders.
Fourth Quarter Financial Highlights
-- Revenue of $35.2 million, an increase of 11% compared to $31.5 million in
the prior year.
-- GAAP gross margin of 63.0%, as compared to 61.5% in the prior year.
Adjusted gross margin (non-GAAP) of 57.7% as compared to 54.7% in the
prior year.
-- Net loss of $11.6 million, compared to a net loss of $8.8 million in the
prior year.
-- Net cash usage during the quarter was $4.4 million, compared to net cash
usage of $6.4 million in the prior year. The Company ended 2024 with
$291.7 million of cash, cash equivalents, marketable securities, and
restricted cash.
Full Year 2024 Financial Highlights
-- Revenue of $137.4 million, an increase of 12% compared to $122.4 million
in the prior year.
-- GAAP gross margin of 60.5%, as compared to 60.7% in the prior year.
Adjusted gross margin (non-GAAP) of 54.6% as compared to 54.0% in the
prior year.
-- Net loss of $38.5 million, a decrease of $10.2 million compared to the
prior year.
-- Net cash usage during the year was $32.2 million, compared to net cash
usage of $17.4 million in the prior year.
Operational and Business Highlights
-- Announced the Company's plan to launch Simoa ONE, a new instrument, by
the end of 2025. Simoa ONE is expected to enable up to a 10-fold increase
in sensitivity over current Simoa instruments and to allow a substantial
increase in plexing and specificity, while maintaining a simple and
efficient workflow.
-- Acquired EMISSION, a manufacturer of large-scale, highly-uniform
dye-encapsulating magnetic beads designed for low and mid-plex assays and
a mid-plex platform that reads its proprietary beads. The acquisition of
EMISSION allows Quanterix to secure the supply of highly controlled beads
for use in its next generation Simoa ONE platform. It also allows the
Company to develop a new multi-plex segment targeting third-party OEM
customers for these beads, which the Company has branded as Nova Beads,
https://www.quanterix.com/nova-beads/.
-- Launched 20 new assays in 2024, including fully automated Simoa$(R)$
Cytokine 4-Plex Advantage PLUS Assays - combining Simoa(R) digital
immunoassay technology and the Company's innovative Advantage PLUS assay
platform. Additionally, the Company launched the Simoa(R) PSD-95
Advantage PLUS Assay measuring postsynaptic density protein 95 (PSD-95),
an essential component of synaptic signaling complexes, playing a pivotal
role in synaptic plasticity and cognitive function.
-- Received Breakthrough Designation from the FDA for LucentAD Complete, a
multi-marker algorithmic test that combines five biomarkers (p-Tau 217,
A<BETA>42, A<BETA> 40, NfL, and GFAP).
-- Significant progress in building global infrastructure for Alzheimer's
disease testing through 12 new partnerships, including with Neurogen,
Innovita, Neurocode, NSW Health Pathology, and IDOR -- Lab Richet in the
fourth quarter.
2025 Full Year Business Outlook
For 2025, on a standalone basis not giving effect to the planned acquisition of Akoya, the Company expects to report revenues in a range $140.0 million to $146.0 million, which represents growth of 2% to 6% over 2024. This estimate excludes revenue from Lucent Diagnostics testing. The Company expects gross margin to be in the range of 59 to 63%, and adjusted gross margin (non-GAAP) in the range of 53% to 57%. Finally, the Company anticipates 2025 cash usage (change in cash, cash equivalents, marketable securities, and restricted cash) to be approximately $55.0 million to $65.0 million, which includes $20.0 million of upfront payments for the EMISSION acquisition. The estimated cash usage excludes any expenses or payments related to the pending Akoya acquisition.
For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.
Conference Call
In conjunction with this announcement, the Company will host a conference call on March 17, 2025, at 4:30 PM E.T. The dial-in number for USA & Canada is Toll-Free (888) 594-4144 or (646) 968-2525 and the conference ID is 4306988.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix at https://ir.quanterix.com. An archived webcast replay will be available on the Company's website for one year.
Financial Highlights
QUANTERIX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except per share data)
Three Months Ended Twelve Months Ended
December 31, December 31, 2024
-------------------- -----------------------
2024 2023 2024 2023
------- ------- ------- -------
Revenues:
Product revenue $ 20,489 $ 20,821 $ 79,740 $ 79,670
Service and
other revenue 11,922 10,230 51,244 40,089
Collaboration
and license
revenue 1,696 146 4,452 1,380
Grant revenue 1,055 352 1,985 1,229
------- ------- ------- -------
Total revenues 35,162 31,549 137,421 122,368
Costs of goods
sold and
services:
Cost of product
revenue 7,843 7,314 33,304 29,103
Cost of service
and other
revenue 5,149 4,829 21,013 19,041
------- ------- ------- -------
Total costs of
goods sold and
services 12,992 12,143 54,317 48,144
------- ------- ------- -------
Gross profit 22,170 19,406 83,104 74,224
------- ------- ------- -------
Operating
expenses:
Research and
development 8,067 7,210 31,082 26,064
Selling,
general and
administrative 28,591 23,436 101,618 89,111
Other lease
costs 279 1,016 3,020 3,712
Impairment and
restructuring -- 1,361 -- 1,328
------- ------- ------- -------
Total operating
expenses 36,937 33,023 135,720 120,215
------- ------- ------- -------
Loss from
operations (14,767) (13,617) (52,616) (45,991)
Interest income,
net 3,491 4,319 14,655 15,839
Other income
(expense), net (357) 626 (136) 2,517
------- ------- ------- -------
Loss before
income taxes (11,633) (8,672) (38,097) (27,635)
Income tax
expense 8 (141) (434) (719)
------- ------- ------- -------
Net loss $(11,625) $ (8,813) $(38,531) $(28,354)
======= ======= ======= =======
Net loss per
common share,
basic and
diluted $ (0.30) $ (0.23) $ (1.00) $ (0.75)
Weighted-average
common shares
outstanding,
basic and
diluted 38,551 37,594 38,367 37,594
QUANTERIX CORPORATION
CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except per share data)
December 31, 2024 December 31, 2023
------------------- -------------------
ASSETS
Current assets:
Cash and cash equivalents $ 56,709 $ 174,422
Marketable securities 232,413 146,902
Accounts receivable, net of
allowance for expected credit
losses 32,141 25,414
Inventory 32,775 26,123
Prepaid expenses and other
current assets 9,556 9,234
--- -------------- --- --------------
Total current assets 363,594 382,095
Restricted cash 2,610 2,604
Property and equipment, net 17,150 17,926
Intangible assets, net 4,031 6,034
Operating lease right-of-use
assets 16,339 18,251
Other non-current assets 2,809 1,657
--- -------------- --- --------------
Total assets $ 406,533 $ 428,567
=== ============== === ==============
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities:
Accounts payable $ 6,953 $ 5,048
Accrued compensation and
benefits 12,620 14,170
Accrued expenses and other
current liabilities 8,851 6,055
Deferred revenue 8,827 9,468
Operating lease liabilities 4,756 4,241
--- -------------- --- --------------
Total current liabilities 42,007 38,982
Deferred revenue, net of current
portion 1,073 1,227
Operating lease liabilities, net
of current portion 32,615 37,223
Other non-current liabilities 800 1,177
--- -------------- --- --------------
Total liabilities 76,495 78,609
--- -------------- --- --------------
Total stockholders' equity 330,038 349,958
--- -------------- --- --------------
Total liabilities and
stockholders' equity $ 406,533 $ 428,567
=== ============== === ==============
QUANTERIX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
Year Ended December 31,
-----------------------------
2024 2023
--------- ---------
Cash flows from operating activities:
Net loss $ (38,531) $ (28,354)
Adjustments to reconcile net loss to
net cash used in operating
activities:
Depreciation and amortization expense 6,463 6,275
Credit losses (gains) on accounts
receivable 588 336
Accretion of marketable securities (6,833) (1,964)
Operating lease right-of-use asset
amortization 1,893 2,015
Stock-based compensation expense 19,987 16,823
Impairment -- 1,361
Other operating activity 55 (150)
Changes in assets and liabilities:
Accounts receivable (7,704) (6,695)
Inventory (6,679) (8,944)
Prepaid expenses and other current
assets (443) (2,371)
Other non-current assets (1,215) (717)
Accounts payable 723 1,189
Accrued compensation and benefits,
accrued expenses, and other
current liabilities 1,398 4,410
Deferred revenue (794) 635
Operating lease liabilities (4,075) (2,645)
Other non-current liabilities 3 (53)
--------- ---------
Net cash used in operating activities (35,164) (18,849)
--------- ---------
Cash flows from investing activities:
Purchases of marketable debt securities (295,606) (175,613)
Proceeds from maturities of marketable
securities 216,709 31,000
Purchases of property and equipment (3,368) (3,841)
--------- ---------
Net cash used in investing activities (82,265) (148,454)
--------- ---------
Cash flows from financing activities:
Proceeds from common stock issued under
stock plans 3,066 2,889
Payments for employee taxes withheld on
stock-based compensation awards (2,610) (198)
--------- ---------
Net cash provided by financing activities 456 2,691
--------- ---------
Net decrease in cash, cash equivalents,
and restricted cash (116,973) (164,612)
Effect of exchange rate changes on
cash, cash equivalents, and restricted
cash (734) 301
Cash, cash equivalents, and restricted
cash at beginning of period 177,026 341,337
--------- ---------
Cash, cash equivalents, and restricted
cash at end of period $ 59,319 $ 177,026
========= =========
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present the following non-GAAP financial measures:
-- Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as
net income (loss) adjusted to exclude interest income, income tax expense
(benefit), depreciation and amortization expense, stock-based
compensation expense, acquisition related costs, impairment and
restructuring, and certain other items which include other charges or
benefits resulting from transactions or events that are highly variable,
significant in size, and that we do not believe are indicative of ongoing
or future business operations (such as, for example, the costs we
incurred in 2024 in connection with the restatement of our previously
issued financial statements). These items are discussed in more detail
below the tables reconciling the GAAP to non-GAAP measures. Adjusted
EBITDA margin is calculated as adjusted EBITDA divided by total revenues.
-- Adjusted gross profit, adjusted gross margin, adjusted total operating
expenses, and adjusted loss from operations: We calculate these non-GAAP
financial measures by including shipping and handling costs for product
sales within cost of product revenue instead of within selling, general
and administrative expenses. Adjusted gross margin is calculated as
adjusted gross profit divided by total revenues.
We believe that presentation of these non-GAAP financial measures provides supplemental information useful to investors in understanding our underlying operating results and trends. We use these non-GAAP financial measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. We believe that presentation of these non-GAAP financial measures provides useful information to investors in assessing our operating performance within our industry and to allow comparability with the presentation of other companies in our industry, such as the inclusion of shipping and handling costs in cost of goods sold for products.
The non-GAAP financial measures presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP. For example, adjusted EBITDA excludes a number of expense items that are included in net loss. As a result, positive adjusted EBITDA may be achieved even where we record a significant net loss in accordance with U.S. GAAP.
Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned "Reconciliation of GAAP to Non-GAAP Financial Measures" in the section below.
Additionally, we make certain forward-looking statements about our future financial performance that include non-GAAP financial measures, which are difficult to predict for future periods because the nature of the adjustments pertains to events that have not yet occurred. We do not forecast many of the excluded items for internal use and therefore information reconciling forward-looking non-GAAP financial measures to U.S. GAAP financial measures is not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from U.S. GAAP to calculate non-GAAP financial measures could significantly impact our U.S. GAAP results.
Reconciliation of GAAP to Non-GAAP Financial Measures
QUANTERIX CORPORATION Reconciliation of Net Loss to Adjusted EBITDA
(non-GAAP) and Adjusted EBITDA Margin (non-GAAP) (Unaudited, amounts in
thousands except percentages)
Three Months Ended Twelve Months Ended
December 31, December 31,
-------------------------- ---------------------------
2024 2023 2024 2023
------- ------ --- ------- ------- ---
Net loss $(11,628) $(8,813) $(38,531) $(28,354)
Interest income (3,490) (4,319) (14,655) (15,839)
Income tax
expense (8) 141 434 719
Depreciation
and
amortization
expense 1,723 1,432 6,463 6,275
Stock-based
compensation
expense 4,837 4,326 19,987 16,823
Acquisition
related costs
(1) 1,612 -- 1,612 --
Impairment and
restructuring -- 1,328 -- 1,328
Restatement
costs (2) 1,067 -- 1,067 --
------- ------ --- ------- ------- ---
Adjusted EBITDA
(non-GAAP) $ (5,886) $(5,905) $(23,622) $(19,048)
======= ====== ======= =======
Total revenues $ 35,161 $31,549 137,421 122,368
Adjusted EBITDA
margin
(non-GAAP)
(adjusted EBITDA
as a % of
revenue) (16.7)% (18.7)% (17.2)% (15.6)%
(1) Represents transaction costs directly related to mergers and acquisitions
including professional and consulting fees supporting due diligence,
legal, and accounting activities associated with acquisitions.
(2) Costs associated with the restatement of previously issued financial
statements, which was completed at the end of 2024.
QUANTERIX CORPORATION Reconciliation of Gross Profit, Gross Margin, Total
Operating Expenses and Loss from Operations to Non-GAAP Financial Measures
(Unaudited, amounts in thousands except percentages)
Three Months Ended December Twelve Months Ended
31, December 31,
--------------------------- ---------------------------
2024 2023 2024 2023
------- ------- --- ------- ------- ---
Gross profit $ 22,169 $ 19,406 $ 83,104 $ 74,224
Shipping and
handling
costs (1,885) (2,142) (8,113) (8,146)
------- ------- ------- -------
Adjusted gross
profit
(non-GAAP) $ 20,284 $ 17,264 $ 74,991 $ 66,078
------- ------- --- ------- ------- ---
Total revenues $ 35,161 $ 31,549 $137,421 $122,368
Gross margin
(gross profit
as % of total
revenues) 63.0% 61.5% 60.5% 60.7%
Adjusted gross
margin
(non-GAAP)
(adjusted gross
profit as % of
total
revenues) 57.7% 54.7% 54.6% 54.0%
Total operating
expenses $ 36,938 $ 33,023 $135,720 $120,215
Shipping and
handling
costs (1,885) (2,142) (8,113) (8,146)
------- ------- ------- -------
Adjusted total
operating
expenses
(non-GAAP) $ 35,053 $ 30,881 $127,607 $112,069
------- ------- --- ------- ------- ---
Loss from
operations $(14,769) $(13,617) $(52,616) $(45,991)
======= ======= ======= =======
Adjusted loss
from operations
(non-GAAP) $(14,769) $(13,617) $(52,616) $(45,991)
======= ======= ======= =======
About Quanterix
From discovery to diagnostics, Quanterix's ultra-sensitive biomarker detection is driving breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,200 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
IMPORTANT ADDITIONAL INFORMATION
In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix (the "Merger"), Quanterix filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4, dated February 13, 2025 (the "Registration Statement"), which contains a preliminary joint proxy statement of Quanterix and Akoya and a preliminary prospectus of Quanterix (the "Joint Proxy Statement/Prospectus"), and each of Quanterix and Akoya may file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of the Joint Proxy Statement/Prospectus will be mailed to Quanterix and Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Joint Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC's website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix's website, at www.quanterix.com, or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya's website, at www.akoyabio.com, or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752 ATTN: Chief Legal Officer.
PARTICIPANTS IN THE SOLICITATION
Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Quanterix or Akoya in respect of the proposed transaction. Information about Quanterix's directors and executive officers is available in the Joint Proxy Statement/Prospectus, and other documents filed by Quanterix with the SEC. Information about Akoya's directors and executive officers is available in the Joint Proxy Statement/Prospectus and Akoya's proxy statement dated April 23, 2024, for its 2024 Annual Meeting of Stockholders, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Joint Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the definitive Joint Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above.
NO OFFER OR SOLICITATION
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix's future business outlook, operations, strategy and financial performance, including statements under the header "2025 Full Year Business Outlook," and statements about the Merger. Words and phrases such as "may," "approximately," "continue," "should," "expects," "projects," "anticipates," "is likely," "look ahead, " "look forward," "believes," "will," "intends," "estimates," "strategy, " "plan," "could," "potential," "possible" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix's future business, operations, strategy and financial performance: risks associated with the anticipated timing for launch of, and features of, Quanterix's next-generation instrument, Simoa ONE; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisition of Emission, Inc.; that Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to the restatement of Quanterix's consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation; risks related to Quanterix's ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation; Quanterix's ability to realize the intended benefits of its assay redevelopment program; and Quanterix's ability to retain and expand its customer base and achieve sufficient market acceptance of its products. Such risks and uncertainties include, among others, the following possibilities with respect to the Merger: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the merger agreement between Quanterix and Akoya; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain necessary stockholder approvals or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits and synergies of the Merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management's attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; changes in Quanterix's share price before the closing of the Merger; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger; and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the Joint Proxy Statement/Prospectus, and in periodic reports filed by Quanterix and Akoya with the SEC, including the "Risk Factors" sections contained therein, which are available on the SEC's website at www.sec.gov.
All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix's or Akoya's underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317014926/en/
CONTACT: Media:
Marissa Klaassen
(978) 488-1854
media@quanterix.com
Investor Relations:
Joshua Young
$(508.SI)$ 846-3327
ir@quanterix.com
(END) Dow Jones Newswires
March 17, 2025 16:01 ET (20:01 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。